UB Paderborn / Katalog / Suche / in CDI

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

PloS one, 2017-08, Vol.12 (8), p.e0183191-e0183191

2017

Volltextzugriff (PDF)

Characteristics and Risk Factors Associated with SARS-CoV-2 Pneumonias in Hospitalized Pediatric Patients: A Pilot Study

Children (Basel), 2023-10, Vol.10 (10), p.1703

2023

Volltextzugriff (PDF)

Changes in Invasive Pneumococcal Disease in the Paediatric Population in the Second COVID-19 Pandemic Year

Vaccines (Basel), 2023-09, Vol.11 (10), p.1548

2023

Volltextzugriff (PDF)

Recurrent invasive pneumococcal disease in children: underlying clinical conditions, and immunological and microbiological characteristics

PloS one, 2015-03, Vol.10 (3), p.e0118848-e0118848

2015

Volltextzugriff (PDF)

Multisystem inflammatory syndrome in children (MIS-C) and sepsis differentiation by a clinical and analytical score: MISSEP score

European journal of pediatrics, 2023-11, Vol.182 (11), p.5109-5118

2023

Volltextzugriff (PDF)

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain

Emerging infectious diseases, 2020-06, Vol.26 (6), p.1147-1155

2020

Volltextzugriff (PDF)

Nirsevimab immunization's real‐world effectiveness in preventing severe bronchiolitis: A test‐negative case–control study

Pediatric allergy and immunology, 2024-06, Vol.35 (6), p.e14175-n/a

2024

Volltextzugriff (PDF)

Rapid Increase of Oral Bacteria in Nasopharyngeal Microbiota After Antibiotic Treatment in Children With Invasive Pneumococcal Disease

Frontiers in cellular and infection microbiology, 2021-10, Vol.11, p.744727-744727

2021

Volltextzugriff (PDF)

Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study

Vaccine, 2011-11, Vol.29 (48), p.9020-9025

2011

Volltextzugriff (PDF)

Differential nasopharyngeal microbiota composition in children according to respiratory health status

Microbial genomics, 2021-10, Vol.7 (10)

2021

Volltextzugriff (PDF)

Abdominal pain as a guide symptom of fever of unknown origin

Enfermedades infecciosas y microbiologia clinica (English ed.), 2024-01, Vol.42 (1), p.55-56

2024

Volltextzugriff (PDF)

PsrP, a Protective Pneumococcal Antigen, Is Highly Prevalent in Children with Pneumonia and Is Strongly Associated with Clonal Type

Clinical and Vaccine Immunology, 2010-11, Vol.17 (11), p.1672-1678

2010

Volltextzugriff (PDF)

Safety and effectiveness of bubble continuous positive airway pressure as respiratory support for bronchiolitis in a pediatric ward

European journal of pediatrics, 2022-12, Vol.181 (12), p.4039-4047

2022

Volltextzugriff (PDF)

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

Enfermedades infecciosas y microbiologia clinica (English ed.), 2021-12, Vol.39 (10), p.486-492

2021

Volltextzugriff (PDF)

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Pediatric pulmonology, 2019-05, Vol.54 (5), p.517-524

2019

Volltextzugriff (PDF)

Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions

Pediatric blood & cancer, 2017-05, Vol.64 (5), p.n/a

2017

Volltextzugriff (PDF)

Enfermedad neumocócica invasiva en niños menores de 60 meses, antes y después de la introducción de la vacuna conjugada 13-valente

Anales de pediatría (Barcelona, Spain : 2003), 2022-06, Vol.96 (6), p.501-510

2022

Volltextzugriff (PDF)

Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine

Anales de Pediatría, 2022-06, Vol.96 (6), p.501-510

2022

Volltextzugriff (PDF)

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

Enfermedades infecciosas y microbiologia clinica (English ed.), 2021-12, Vol.39 (10), p.486-492

2021

Volltextzugriff (PDF)

COVID-19 admissions: Trying to define the real impact of infection in hospitalized patients

Anales de Pediatría, 2024-05, Vol.100 (5), p.342-351

2024

Volltextzugriff (PDF)

Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes

Vaccine, 2013-01, Vol.31 (6), p.960-966

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

Characteristics and Risk Factors Associated with SARS-CoV-2 Pneumonias in Hospitalized Pediatric Patients: A Pilot Study

Changes in Invasive Pneumococcal Disease in the Paediatric Population in the Second COVID-19 Pandemic Year

Recurrent invasive pneumococcal disease in children: underlying clinical conditions, and immunological and microbiological characteristics

Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study

Multisystem inflammatory syndrome in children (MIS-C) and sepsis differentiation by a clinical and analytical score: MISSEP score

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain

Low transmission of SARS-CoV-2 derived from children in family clusters: An observational study of family households in the Barcelona Metropolitan Area, Spain

Nirsevimab immunization's real‐world effectiveness in preventing severe bronchiolitis: A test‐negative case–control study

Rapid Increase of Oral Bacteria in Nasopharyngeal Microbiota After Antibiotic Treatment in Children With Invasive Pneumococcal Disease

Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study

Differential nasopharyngeal microbiota composition in children according to respiratory health status

Abdominal pain as a guide symptom of fever of unknown origin

PsrP, a Protective Pneumococcal Antigen, Is Highly Prevalent in Children with Pneumonia and Is Strongly Associated with Clonal Type

Safety and effectiveness of bubble continuous positive airway pressure as respiratory support for bronchiolitis in a pediatric ward

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions

Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine

Enfermedad neumocócica invasiva en niños menores de 60 meses, antes y después de la introducción de la vacuna conjugada 13-valente

Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine

Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

COVID-19 admissions: Trying to define the real impact of infection in hospitalized patients

SARS-CoV-2 transmission in teenagers and young adults in Fútbol Club Barcelona’s Multidisciplinary Sports Training Academy

Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes

Suchergebnisse filtern